King's College London

Research portal

Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial

Research output: Contribution to journalReview article

Tora S Solheim, Barry J A Laird, Trude R Balstad, Asta Bye, Guro Stene, Vickie Baracos, Florian Strasser, Gareth Griffiths, Matthew Maddocks, Marie Fallon, Stein Kaasa, Kenneth Fearon

Original languageEnglish
JournalBMJ Supportive and Palliative Care
Early online date9 Feb 2018
DOIs
Publication statusE-pub ahead of print - 9 Feb 2018

Documents

King's Authors

Abstract

Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomised controlled trial of a multimodal cachexia intervention is under way. Termed the MENAC trial (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of non-steroidal anti-inflammatory drugs and eicosapentaenoic acid to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial.

TRIAL REGISTRATION NUMBER: NCT02330926.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454